Topline results from investigational nAMD drop SYL1801 (Sylentis)

News
Article

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

A pharmacist helps a customer access medication. Concept image for neovascular age-related macular degeneration eye drop treatment therapy. Image credit: ©Gorodenkoff – stock.adobe.com

Sylentis presented results from the phase 2a study in a poster at the Association for Research in Vision and Ophthalmology meeting. Image credit: ©Gorodenkoff – stock.adobe.com

Sylentis recently announced topline results from the SYL1801_II phase 2a study investigating SYL1801 for the treatment of neovascular age-related macular degeneration (nAMD).1 SYL1801 is an investigational small interfering RNA (siRNA) therapy administered via eye drops, rather than intravitreal injection, to treat nAMD. Sylentis, based in Madrid, Spain, said the primary endpoint was reached and more than 71% of patients in the mid-dose level maintained visual acuity over the 6-week study period.

"With these data from this explorative study of SYL1801, we are encouraged to put efforts into the subsequent clinical research program with proper guidance from the patient outcomes in the concluded study,” said Andreas Segerros, CEO of Sylentis.

Three parallel dose level cohorts of SYL1801 were evaluated in a double-blind study. A total of 99 subjects with treatment-naïve eyes of nAMD were followed for 42 days. The primary endpoint was to evaluate the effect of SYL1801 on the chance from baseline to the end of treatment in best corrected visual acuity (BCVA) score, according to the company’s press release. Throughout the study’s duration, it was found that all dose-levels of SYL1801 maintained visual acuity similarly, with the middle concentration of 25mg/mh achieving a statistically significant improvement of visual acuity at 42 days.

The company presented these results in a poster titled “AMD, Clinical Research,” at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting held 4-8 May in Salt Lake City.

Reference
1. Sylentis, a PharmaMar Group company, announces the positive results of the Phase IIa dose-ranging study for SYL1801 in patients with Age-Related Macular Degeneration (AMD) – Sylentis. Sylentis.com. Published 2025. Accessed May 15, 2025. https://sylentis.com/sylentis-a-pharmamar-group-company-announces-the-positive-results-of-the-phase-iia-dose-ranging-study-for-syl1801-in-patients-with-age-related-macular-degeneration-amd/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.